Cargando…

Naringenin potentiates anti-tumor immunity against oral cancer by inducing lymph node CD169-positive macrophage activation and cytotoxic T cell infiltration

The CD169(+) macrophages in lymph nodes are implicated in cytotoxic T lymphocyte (CTL) activation and are associated with improved prognosis in several malignancies. Here, we investigated the significance of CD169(+) macrophages in oral squamous cell carcinoma (OSCC). Further, we tested the anti-tum...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawaguchi, Sho, Kawahara, Kenta, Fujiwara, Yukio, Ohnishi, Koji, Pan, Cheng, Yano, Hiromu, Hirosue, Akiyuki, Nagata, Masashi, Hirayama, Masatoshi, Sakata, Junki, Nakashima, Hikaru, Arita, Hidetaka, Yamana, Keisuke, Gohara, Shunsuke, Nagao, Yuka, Maeshiro, Manabu, Iwamoto, Asuka, Hirayama, Mayumi, Yoshida, Ryoji, Komohara, Yoshihiro, Nakayama, Hideki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9374624/
https://www.ncbi.nlm.nih.gov/pubmed/35044489
http://dx.doi.org/10.1007/s00262-022-03149-w
_version_ 1784767825895751680
author Kawaguchi, Sho
Kawahara, Kenta
Fujiwara, Yukio
Ohnishi, Koji
Pan, Cheng
Yano, Hiromu
Hirosue, Akiyuki
Nagata, Masashi
Hirayama, Masatoshi
Sakata, Junki
Nakashima, Hikaru
Arita, Hidetaka
Yamana, Keisuke
Gohara, Shunsuke
Nagao, Yuka
Maeshiro, Manabu
Iwamoto, Asuka
Hirayama, Mayumi
Yoshida, Ryoji
Komohara, Yoshihiro
Nakayama, Hideki
author_facet Kawaguchi, Sho
Kawahara, Kenta
Fujiwara, Yukio
Ohnishi, Koji
Pan, Cheng
Yano, Hiromu
Hirosue, Akiyuki
Nagata, Masashi
Hirayama, Masatoshi
Sakata, Junki
Nakashima, Hikaru
Arita, Hidetaka
Yamana, Keisuke
Gohara, Shunsuke
Nagao, Yuka
Maeshiro, Manabu
Iwamoto, Asuka
Hirayama, Mayumi
Yoshida, Ryoji
Komohara, Yoshihiro
Nakayama, Hideki
author_sort Kawaguchi, Sho
collection PubMed
description The CD169(+) macrophages in lymph nodes are implicated in cytotoxic T lymphocyte (CTL) activation and are associated with improved prognosis in several malignancies. Here, we investigated the significance of CD169(+) macrophages in oral squamous cell carcinoma (OSCC). Further, we tested the anti-tumor effects of naringenin, which has been previously shown to activate CD169(+) macrophages, in a murine OSCC model. Immunohistochemical analysis for CD169 and CD8 was performed on lymph node and primary tumor specimens from 89 patients with OSCC. We also evaluated the effects of naringenin on two murine OSCC models. Increased CD169(+) macrophage counts in the regional lymph nodes correlated with favorable prognosis and CD8(+) cell counts within tumor sites. Additionally, naringenin suppressed tumor growth in two murine OSCC models. The mRNA levels of CD169, interleukin (IL)-12, and C-X-C motif chemokine ligand 10 (CXCL10) in lymph nodes and CTL infiltration in tumors significantly increased following naringenin administration in tumor-bearing mice. These results suggest that CD169(+) macrophages in lymph nodes are involved in T cell-mediated anti-tumor immunity and could be a prognostic marker for patients with OSCC. Moreover, naringenin is a new potential agent for CD169(+) macrophage activation in OSCC treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00262-022-03149-w.
format Online
Article
Text
id pubmed-9374624
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-93746242022-08-14 Naringenin potentiates anti-tumor immunity against oral cancer by inducing lymph node CD169-positive macrophage activation and cytotoxic T cell infiltration Kawaguchi, Sho Kawahara, Kenta Fujiwara, Yukio Ohnishi, Koji Pan, Cheng Yano, Hiromu Hirosue, Akiyuki Nagata, Masashi Hirayama, Masatoshi Sakata, Junki Nakashima, Hikaru Arita, Hidetaka Yamana, Keisuke Gohara, Shunsuke Nagao, Yuka Maeshiro, Manabu Iwamoto, Asuka Hirayama, Mayumi Yoshida, Ryoji Komohara, Yoshihiro Nakayama, Hideki Cancer Immunol Immunother Original Article The CD169(+) macrophages in lymph nodes are implicated in cytotoxic T lymphocyte (CTL) activation and are associated with improved prognosis in several malignancies. Here, we investigated the significance of CD169(+) macrophages in oral squamous cell carcinoma (OSCC). Further, we tested the anti-tumor effects of naringenin, which has been previously shown to activate CD169(+) macrophages, in a murine OSCC model. Immunohistochemical analysis for CD169 and CD8 was performed on lymph node and primary tumor specimens from 89 patients with OSCC. We also evaluated the effects of naringenin on two murine OSCC models. Increased CD169(+) macrophage counts in the regional lymph nodes correlated with favorable prognosis and CD8(+) cell counts within tumor sites. Additionally, naringenin suppressed tumor growth in two murine OSCC models. The mRNA levels of CD169, interleukin (IL)-12, and C-X-C motif chemokine ligand 10 (CXCL10) in lymph nodes and CTL infiltration in tumors significantly increased following naringenin administration in tumor-bearing mice. These results suggest that CD169(+) macrophages in lymph nodes are involved in T cell-mediated anti-tumor immunity and could be a prognostic marker for patients with OSCC. Moreover, naringenin is a new potential agent for CD169(+) macrophage activation in OSCC treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00262-022-03149-w. Springer Berlin Heidelberg 2022-01-19 2022 /pmc/articles/PMC9374624/ /pubmed/35044489 http://dx.doi.org/10.1007/s00262-022-03149-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Kawaguchi, Sho
Kawahara, Kenta
Fujiwara, Yukio
Ohnishi, Koji
Pan, Cheng
Yano, Hiromu
Hirosue, Akiyuki
Nagata, Masashi
Hirayama, Masatoshi
Sakata, Junki
Nakashima, Hikaru
Arita, Hidetaka
Yamana, Keisuke
Gohara, Shunsuke
Nagao, Yuka
Maeshiro, Manabu
Iwamoto, Asuka
Hirayama, Mayumi
Yoshida, Ryoji
Komohara, Yoshihiro
Nakayama, Hideki
Naringenin potentiates anti-tumor immunity against oral cancer by inducing lymph node CD169-positive macrophage activation and cytotoxic T cell infiltration
title Naringenin potentiates anti-tumor immunity against oral cancer by inducing lymph node CD169-positive macrophage activation and cytotoxic T cell infiltration
title_full Naringenin potentiates anti-tumor immunity against oral cancer by inducing lymph node CD169-positive macrophage activation and cytotoxic T cell infiltration
title_fullStr Naringenin potentiates anti-tumor immunity against oral cancer by inducing lymph node CD169-positive macrophage activation and cytotoxic T cell infiltration
title_full_unstemmed Naringenin potentiates anti-tumor immunity against oral cancer by inducing lymph node CD169-positive macrophage activation and cytotoxic T cell infiltration
title_short Naringenin potentiates anti-tumor immunity against oral cancer by inducing lymph node CD169-positive macrophage activation and cytotoxic T cell infiltration
title_sort naringenin potentiates anti-tumor immunity against oral cancer by inducing lymph node cd169-positive macrophage activation and cytotoxic t cell infiltration
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9374624/
https://www.ncbi.nlm.nih.gov/pubmed/35044489
http://dx.doi.org/10.1007/s00262-022-03149-w
work_keys_str_mv AT kawaguchisho naringeninpotentiatesantitumorimmunityagainstoralcancerbyinducinglymphnodecd169positivemacrophageactivationandcytotoxictcellinfiltration
AT kawaharakenta naringeninpotentiatesantitumorimmunityagainstoralcancerbyinducinglymphnodecd169positivemacrophageactivationandcytotoxictcellinfiltration
AT fujiwarayukio naringeninpotentiatesantitumorimmunityagainstoralcancerbyinducinglymphnodecd169positivemacrophageactivationandcytotoxictcellinfiltration
AT ohnishikoji naringeninpotentiatesantitumorimmunityagainstoralcancerbyinducinglymphnodecd169positivemacrophageactivationandcytotoxictcellinfiltration
AT pancheng naringeninpotentiatesantitumorimmunityagainstoralcancerbyinducinglymphnodecd169positivemacrophageactivationandcytotoxictcellinfiltration
AT yanohiromu naringeninpotentiatesantitumorimmunityagainstoralcancerbyinducinglymphnodecd169positivemacrophageactivationandcytotoxictcellinfiltration
AT hirosueakiyuki naringeninpotentiatesantitumorimmunityagainstoralcancerbyinducinglymphnodecd169positivemacrophageactivationandcytotoxictcellinfiltration
AT nagatamasashi naringeninpotentiatesantitumorimmunityagainstoralcancerbyinducinglymphnodecd169positivemacrophageactivationandcytotoxictcellinfiltration
AT hirayamamasatoshi naringeninpotentiatesantitumorimmunityagainstoralcancerbyinducinglymphnodecd169positivemacrophageactivationandcytotoxictcellinfiltration
AT sakatajunki naringeninpotentiatesantitumorimmunityagainstoralcancerbyinducinglymphnodecd169positivemacrophageactivationandcytotoxictcellinfiltration
AT nakashimahikaru naringeninpotentiatesantitumorimmunityagainstoralcancerbyinducinglymphnodecd169positivemacrophageactivationandcytotoxictcellinfiltration
AT aritahidetaka naringeninpotentiatesantitumorimmunityagainstoralcancerbyinducinglymphnodecd169positivemacrophageactivationandcytotoxictcellinfiltration
AT yamanakeisuke naringeninpotentiatesantitumorimmunityagainstoralcancerbyinducinglymphnodecd169positivemacrophageactivationandcytotoxictcellinfiltration
AT goharashunsuke naringeninpotentiatesantitumorimmunityagainstoralcancerbyinducinglymphnodecd169positivemacrophageactivationandcytotoxictcellinfiltration
AT nagaoyuka naringeninpotentiatesantitumorimmunityagainstoralcancerbyinducinglymphnodecd169positivemacrophageactivationandcytotoxictcellinfiltration
AT maeshiromanabu naringeninpotentiatesantitumorimmunityagainstoralcancerbyinducinglymphnodecd169positivemacrophageactivationandcytotoxictcellinfiltration
AT iwamotoasuka naringeninpotentiatesantitumorimmunityagainstoralcancerbyinducinglymphnodecd169positivemacrophageactivationandcytotoxictcellinfiltration
AT hirayamamayumi naringeninpotentiatesantitumorimmunityagainstoralcancerbyinducinglymphnodecd169positivemacrophageactivationandcytotoxictcellinfiltration
AT yoshidaryoji naringeninpotentiatesantitumorimmunityagainstoralcancerbyinducinglymphnodecd169positivemacrophageactivationandcytotoxictcellinfiltration
AT komoharayoshihiro naringeninpotentiatesantitumorimmunityagainstoralcancerbyinducinglymphnodecd169positivemacrophageactivationandcytotoxictcellinfiltration
AT nakayamahideki naringeninpotentiatesantitumorimmunityagainstoralcancerbyinducinglymphnodecd169positivemacrophageactivationandcytotoxictcellinfiltration